Samsung Life and Samsung Fire Report Strong Q1 Results Driven by Samsung Electronics Samsung Life and Samsung Fire reported solid performances for the first quarter of this year. The increase in sales of health insurance products, improvements in investment income, and gains from the rising stock price of Samsung Electronics contributed to significant enhancements in their capital soundness. According to the Financial Supervisory Service's electronic disclosure system on May 14, Samsung Life's net profit attributable to shareholders for the first quarter reached 1.2036 trillion won, marking an 89.5% increase compared to the same period last year. The rise in investment income, which increased by 125.5% to 1.2729 trillion won, was bolstered by dividend income, increased profits from subsidiaries, and the reversal of a provision worth approximately 400 billion won following a legal victory in an immediate annuity lawsuit last year. Samsung Fire also saw a slight increase in net profit, supported by stable earnings from long-term insurance. However, the auto insurance sector reported a loss of 9.6 billion won due to premium reductions and an increase in claims. Samsung Fire anticipates improvements in auto insurance loss ratios with the upcoming implementation of the '8-week rule' aimed at curbing excessive medical treatments for patients. Both companies benefited from the positive impact of Samsung Electronics' stock performance on their financial capabilities. Notably, Samsung Life, the largest shareholder of Samsung Electronics, saw its equity rise from 64.8 trillion won at the end of last year to 83.3 trillion won by the end of March this year, with the increase attributed to 16.6 trillion won in evaluation gains related to Samsung Electronics. As a result, Samsung Life's K-ICS (solvency) ratio stood at 210% as of the end of March, up 12 percentage points from the end of last year. Samsung Fire also maintained a stable K-ICS ratio in the 270% range, continuing to demonstrate the highest capital strength in the industry. Samsung Life plans to leverage its increased capital strength to enhance shareholder returns while expanding into new business areas. Iwan Sam, Chief Financial Officer of Samsung Life, stated, "Since the K-ICS for the first quarter exceeded our target level, we plan to actively utilize surplus funds to enhance shareholder value and as investment resources. We are also considering expanding into new business areas, including overseas mergers and acquisitions in insurance and asset management, as well as healthcare and senior living sectors."* This article has been translated by AI. 2026-05-14 19:39:59

Russia Launches Major Drone and Missile Attack on Kyiv Amid Trump-Xi Talks Russia has launched a large-scale drone and missile attack across Ukraine, including the capital Kyiv. This assault coincided with discussions between U.S. President Donald Trump and Chinese President Xi Jinping in Beijing regarding the war in Ukraine, prompting Ukraine to criticize the attack as evidence of Russia's lack of willingness for peace negotiations. According to the Kyiv Post and CNN, the Ukrainian Air Force reported that Russia fired a total of 731 aerial weapons overnight, including 675 drones and 56 missiles. The primary target of the attack was Kyiv. Russia deployed Kinzhal air-launched ballistic missiles, Iskander-M ballistic missiles, Kh-101 cruise missiles, Shahed-type attack drones, and decoy unmanned aerial vehicles. The Ukrainian Air Force stated that it intercepted or suppressed 693 targets, including 41 missiles and 652 drones. However, 15 missiles and 23 drones struck 24 locations, and debris from intercepted missiles fell in 18 areas. Damage in Kyiv was significant. Mayor Vitali Klitschko reported that part of a nine-story apartment building in the Darnytskyi district was destroyed. Eighteen apartments collapsed, and rescue teams managed to save 11 residents from the rubble. Oleksii Kuleba, Ukraine's Minister of Regional Development, confirmed that one person died in Kyiv. CNN, citing Mayor Klitschko, reported that 32 people were injured, including a one-month-old baby. Damage was also reported in several areas of Kyiv. In the Obolonskyi district, debris from intercepted missiles fell on residential buildings, causing fires. Damage to residential buildings, roads, parked vehicles, and non-residential facilities was reported in the Dniprovskyi, Holosiivskyi, and Solomianskyi districts. The timing of the attack is noteworthy. CNN reported that explosions were heard in Kyiv while President Trump and President Xi were meeting in Beijing. Ukrainian Foreign Minister Dmytro Kuleba criticized on Telegram, stating, "While the world expects peace, predictability, and cooperation, Putin launched hundreds of drones and ballistic and cruise missiles at the Ukrainian capital at the very time the leaders of great powers met in Beijing." He added that "President Trump and President Xi have sufficient influence to tell Putin to end the war." According to Chinese state media, Presidents Trump and Xi discussed the Ukraine war during their meeting, although specific details of their discussions were not immediately disclosed. This attack is interpreted as a saturation strategy aimed at depleting Ukraine's air defense capabilities rather than just a large-scale bombing. Ukrainian officials believe that Russia aimed to weaken air defense munitions and surveillance systems by deploying drones in multiple waves, thereby enhancing the effectiveness of missile strikes. The Kyiv Post noted that Russia had launched approximately 800 drones at Ukraine the previous day, describing this assault as one of the longest and largest continuous bombardments since the war began. Ukrainian officials analyzed that Russia seeks to exert psychological pressure not only through military damage but also on civilians. The attack, coinciding with the Trump-Xi meeting, appears intended to project an impression of Russian superiority on the battlefield to the international community. This airstrike is expected to further highlight the issue of the Ukraine war during the Beijing talks. Ukraine is demanding that the U.S. and China exert substantial pressure on Russia.* This article has been translated by AI. 2026-05-14 19:37:47

Korea's Food and Drug Administration Aims for Faster, Safer Drug Approval System Ahn Young-jin, Director of the Bio-Pharmaceutical Bureau at the Ministry of Food and Drug Safety, emphasized the need to establish the fastest and safest drug approval and review system in line with the era of innovative drug development utilizing artificial intelligence (AI). Speaking at the 16th Global Healthcare Forum held at the Korea Press Center in Jung-gu, Seoul, on May 14, Ahn stated, "Reducing the development time for innovative drugs using AI will provide patients with quicker access to treatment." He further explained that the Ministry will enhance consultations and communication with the industry to keep pace with the speed of industrial innovation and plans to shift from traditional review methods to a system that allows for simultaneous review of multiple data sets. Ahn also introduced the Ministry's initiative to establish an 'AI Drug Review System,' stating, "We will maximize the efficiency of data review using AI and create a support system that allows companies to self-check for errors before submission." Additionally, he announced that through the 'Global Innovative Product Fast Track (GIFT)' program, dedicated reviewers will be assigned from the early stages of development, providing one-on-one consulting to expedite the market entry of innovative products. Ahn highlighted the Ministry's global regulatory capabilities, noting, "The Ministry has been recognized as an excellent regulatory authority by the World Health Organization (WHO) in the fields of pharmaceuticals and vaccines," and added that the 'AIRIS 2025' initiative, held last year, led efforts for global regulatory harmonization in the field of AI-utilized medical products. He expressed hope that the forum would serve as a platform for discussions aimed at enhancing the global competitiveness of Korea's pharmaceutical and bio industries, stating, "The Ministry will actively support K-bio in seizing opportunities in the global market."* This article has been translated by AI. 2026-05-14 19:36:29

Samsung Workers Consider General Strike Amid Union Tensions The movement for a general strike among Samsung Electronics workers is intensifying, drawing attention as employees share their strike experiences on anonymous workplace forums. On May 14, a Samsung employee identified as A posted on the anonymous community "Blind" with the title, "Was it fun to mock Samsung Hyuksu?" In the post, A stated, "Now Samsung Hyuksu will repay with a general strike," adding, "The labor-management relationship is already shattered, and don’t think this general strike will be the last one." A expressed a firm stance, saying, "Whether operating profit hits -100 trillion won or not, we will go all the way." The term "Samsung Hyuksu" is a derogatory reference to Samsung Electronics employees, derived from "Samsung Revolution Defense Corps." The post prompted responses from workers in other industries sharing their own union experiences. One commenter, identifying as a Korea Railroad Corporation employee, wrote, "As someone who has experienced a 74-day strike, I can say that eventually, you end up begging lawmakers from both parties for a reason to return." He recalled, "The union leader at that time was the current Minister of Employment and Labor, Kim Young-hoon," and described striking as a lonely and hungry experience. He added, "I have bought Hyundai Motor and robotics stocks as a hedge." A comment from a Hyundai Motor employee also gained attention. He noted, "Compared to the past decade, there have been almost no strikes at Hyundai in the last five years," explaining that Hyundai strikes are essentially annual events for labor and management to find a middle ground. He continued, "When an actual strike occurs, both sides end up in an awkward situation," and warned that as time passes and wages decrease, workers might think, 'I should have accepted the previous offer.'" He concluded, "From a worker's perspective, a dramatic resolution just before a strike is the best scenario," stating that actual strikes often result in conditions worse than those previously offered by management. Other workers reacted to the comment, saying, "Hyundai's union experience is indeed different," and "The expert perspective is distinct; it's no wonder Hyundai's union is famous." Recently, as the semiconductor market recovers and SK Hynix shows strength in the high-bandwidth memory (HBM) sector, concerns among investors are rising regarding Samsung Electronics due to performance bonus controversies and the potential for a union general strike. Online discussions have included comments like, "Sell Samsung and go for Hynix," "The atmosphere among the staff is already tense," and "It seems the labor-management relationship has completely broken down." Meanwhile, Samsung Electronics and its union have been unable to narrow their differences over wage and performance bonus systems, raising the possibility of a prolonged general strike and increasing tension in the industry.* This article has been translated by AI. 2026-05-14 19:33:42

Korean Pharmaceutical Association VP Pledges Support for Global Success of 'K-Pharma' in AI Era Lee Jae-guk, Vice President of the Korean Pharmaceutical and Bio Association, announced plans to foster an innovative ecosystem that will enable 'K-Pharma' to grow into a global enterprise in the age of artificial intelligence (AI). Speaking at the 16th Global Healthcare Forum hosted by Aju Economy at the Korea Press Center in Jung-gu, Seoul, on May 14, Lee stated, "The domestic and international pharmaceutical and bio industries are entering a transformative era with the introduction of AI." He emphasized that global pharmaceutical giants are now in a competitive phase where AI strategies are yielding tangible results. "AI is changing the paradigm of drug development by being utilized throughout the entire process, from the discovery of drug candidates to the design and execution of clinical trials and regulatory reviews," he explained. "It plays a groundbreaking role in reducing research and development costs and shortening development timelines, and is also recognized as a key growth driver for licensing out and mergers and acquisitions with global big pharma." Lee further outlined his commitment to supporting the technological growth of the domestic pharmaceutical and bio industry to help it transition into a global player. He stated, "The association will actively support the AI revolution in K-pharmaceuticals and the establishment of a global value chain based on our accumulated experience through initiatives like the AI Drug Convergence Research Institute and the K-MELLODDY project, a joint R&D effort with the Ministry of Health and Welfare and the Ministry of Science and ICT." He concluded, "As the pharmaceutical and bio industry is a core strategic sector responsible for public health and the national economy, we will do our utmost to support the global success era of 'K-Pharma' in the AI age."* This article has been translated by AI. 2026-05-14 19:32:43

Youth Future Savings Accounts Offered by 15 Institutions with Interest Rates Up to 8% The 'Youth Future Savings Account,' designed to support asset formation for young people, will be available next month through 15 financial institutions. The maximum interest rate is expected to range from 7% to 8% depending on the institution. On May 14, the Financial Services Commission held an event titled 'The First Step to Filling the Future: Unboxing Talk Concert for Youth Future Savings' at the Small Business Market Promotion Corporation's dedicated training center in Seoul, where it announced the participating institutions and interest rates for the Youth Future Savings Account. This policy financial product combines government contributions with tax-exempt interest income to assist young people in building their initial assets. The participating institutions include major banks such as KB, Shinhan, Woori, Hana, and NH Bank, along with iM Bank and regional banks like Busan, Gyeongnam, Gwangju, and Jeonbuk. New entrants to the program include Suhyup Bank, KakaoBank, Toss Bank, and Korea Post, bringing the total to 15 institutions. The account features a fixed interest rate for three years, starting with a base rate of 5%, plus an additional preferential rate of 2% to 3% depending on the institution. Consequently, the maximum interest rate is projected to be between 7% and 8%. All participating institutions will offer a common preferential rate of 0.5 percentage points for young people with an annual income of 36 million won or less, and an additional 0.2 percentage points for those who complete the 'Financial Counseling for All Youth' program. Considering the government contributions and tax benefits, the effective yield is expected to be even higher. The Financial Services Commission explained that if a participant contributes 500,000 won monthly for three years, they could receive between 21.1 million and 21.38 million won for the standard account, and between 22.27 million and 22.55 million won for the preferential account. This is comparable to the effects of joining a standard savings account with an annual simple interest rate of 13.2% to 14.4%, or a preferential account with rates of 18.2% to 19.4%. The commission also announced improvements to the program. To ensure that young couples who are married are not excluded due to household income criteria, the income requirements will be relaxed for two-person households consisting of the account holder and their spouse. The threshold for the standard account will increase from 200% to 250% of the median income, while the preferential account will rise from 150% to 200%. Additionally, a credit score incentive will be implemented. Young people who maintain their Youth Future Savings Account for more than two years and contribute over 8 million won will receive a credit score boost of 5 to 10 points. If they switch from the Youth Leap Account, the duration and contributions from the previous account will also be considered.* This article has been translated by AI. 2026-05-14 19:18:58

Aribio Signs $4.7 Billion Deal with China's Puxing for Alzheimer's Drug Aribio has successfully secured a global licensing agreement worth approximately 7 trillion won ($4.7 billion) for its oral Alzheimer's treatment, AR1001, with China's Puxing Pharmaceuticals. This marks the largest technology transfer deal in South Korea's dementia treatment sector, with expectations for domestic companies to thrive in a market projected to exceed 70 trillion won by 2030.On May 14, Aribio announced its exclusive licensing agreement with Puxing Pharmaceuticals, which encompasses the development, approval, production, and commercialization of AR1001. The deal covers global market rights excluding South Korea, the Middle East, and Latin America.Upon signing the agreement, Aribio received an upfront payment of $60 million (approximately 90 billion won). Additionally, the company will receive $80 million upon the announcement of top-line results from Phase 3 clinical trials, totaling $140 million (about 210 billion won) in upfront payments. Further milestone payments will be available during the approval and commercialization phases, along with royalties of up to 20%.AR1001 is an oral Alzheimer's treatment classified as a PDE-5 inhibitor, characterized by its multi-target mechanism rather than a single target. It aims to inhibit amyloid and tau pathology while also reducing neuroinflammation, improving cerebral blood flow, and protecting nerve cells.Currently, a global Phase 3 clinical trial involving approximately 1,500 participants is nearing completion in the U.S., Europe, China, and South Korea, with top-line results expected to be released in the second half of this year.An Aribio representative stated, "So far, clinical trials have confirmed safety, blood-brain barrier penetration capability, and potential cognitive function improvement in early patient groups."This agreement is noteworthy in light of the rapidly growing Alzheimer's treatment market. The global market has entered a commercialization phase following the introduction of anti-amyloid antibody treatments such as Eisai and Biogen's Leqembi and Eli Lilly's Donanemab. However, these drugs have faced criticism due to their intravenous administration, safety controversies, and limited efficacy.As a result, there is increasing anticipation for new oral medications with convenient dosing and complex mechanisms. Market research firms project that the global Alzheimer's treatment market, currently valued at around 20 trillion won, will expand to over 70 trillion won by 2030.Jung Jae-jun, co-CEO of Aribio, remarked, "This agreement is a testament to the competitiveness of Korean biotech in the global new drug market, going beyond mere technology transfer."* This article has been translated by AI. 2026-05-14 19:17:46

Rep. Park Hee-seung: AI Marks Turning Point for Pharma and Bio Industries Rep. Park Hee-seung of the Democratic Party of Korea, a member of the National Assembly's Health and Welfare Committee, stated that the global pharmaceutical and biotechnology industries are at a significant turning point driven by artificial intelligence (AI). He explained that AI is enhancing research and development (R&D) efficiency throughout the entire drug development process and is leading to structural changes in the industry. In a written address at the 16th Global Healthcare Forum held on May 14 at the Korea Press Center in Jung-gu, Seoul, hosted by Aju Economy, Park said, "Technological advancements are a key driver facilitating licensing out and mergers and acquisitions (M&A) with global big pharma companies." He emphasized that the K-bio industry must move beyond mere technology validation to establish a comprehensive value chain that attracts capital and enables global expansion. "To secure competitiveness in the rapidly changing global market, strategic policy support and close collaboration among industry, academia, and research institutions are more crucial than ever," he added. As a member of the Health and Welfare Committee, Park pledged to listen to voices from the field, stating, "I will work to create effective policy foundations that allow companies to shorten drug development timelines based on AI technology and successfully enter the global market." He concluded, "I hope today's event serves as an opportunity to seek concrete strategies to enhance the global competitiveness of the K-pharmaceutical and bio industries and for the public and private sectors to pool their wisdom."* This article has been translated by AI. 2026-05-14 19:16:15

Samsung Epise Holdings Accelerates Value Growth with AA ESG Rating and Profit Turnaround Samsung Epise Holdings has received an AA rating from Morgan Stanley Capital International (MSCI) in its first participation in the ESG (Environmental, Social, and Governance) assessment. The holding company also achieved a profit turnaround in the first quarter, bolstered by strong sales of its subsidiary Samsung Bioepis's biosimilars, marking a successful combination of business performance and ESG values.On May 14, Samsung Epise Holdings announced that it earned an AA rating, placing it in the leader group of the MSCI ESG evaluation. This high rating comes after the company publicly shared its management achievements and the ESG activities of its subsidiary, Samsung Bioepis, following its split listing in November of last year.MSCI evaluates publicly traded companies worldwide on environmental (E), social (S), and governance (G) criteria, assigning ratings from AAA to CCC across seven levels. Samsung Epise Holdings received particularly high marks in the social category for its talent management and product safety and quality control.Kim Kyung-ah, CEO of Samsung Epise Holdings, stated, "Achieving a leader rating in our first global ESG assessment is the result of systematically preparing ESG management as a core value since our establishment. We will strengthen our ESG-based sustainable management system alongside the development of patient-centered biopharmaceuticals."Meanwhile, Samsung Bioepis reported first-quarter sales of 454.9 billion won and an operating profit of 144 billion won, reflecting a year-on-year increase of 14% and 13%, respectively. This double-digit growth was driven by solid sales of existing products, such as the biosimilar SB4, which marked its 10th anniversary in Europe, and the impact of new product launches in the United States.The holding company, Samsung Epise Holdings, recorded consolidated first-quarter sales of 453.9 billion won and an operating profit of 90.5 billion won, successfully turning a profit. Following its establishment from the spin-off of Samsung Biologics in November, the holding company had reported sales of 251.7 billion won and an operating loss of 63.6 billion won in its first two months but quickly transitioned to profitability due to the strong performance of its subsidiaries.* This article has been translated by AI. 2026-05-14 19:14:54

SKT and Defense Ministry Collaborate on Defense AI Initiatives The Defense Ministry and SK Telecom (SKT) have joined forces to promote defense artificial intelligence (AI). On May 14, the Defense Ministry, SKT, and the Ministry of Science and ICT signed a memorandum of understanding (MOU) at SKT's headquarters in Euljiro, Seoul, to utilize the ministry's independent AI foundation model in the defense sector. The event was attended by Kim Myung-guk, head of SKT's Industrial AI Division, and Jeon Jun-beom, director of the Defense AI Planning Bureau. The agreement aims to foster collaboration in several areas, including the development and demonstration of defense-specific AI models based on the independent AI foundation model, the collection and provision of open data in the defense sector, and support for GPU utilization linked to national AI projects. This MOU is part of the Ministry of Science and ICT's ongoing independent AI foundation model project, which seeks to accelerate digital transformation in the defense sector. This marks the first time the independent AI foundation model will be applied in defense. Earlier in January, SKT's elite team advanced to the second phase of the independent AI foundation model project with the launch of 'A.X K1,' a super-large AI model exceeding 50 billion parameters. SKT plans to lead the development of defense-specific AI models leveraging its capabilities in large language model (LLM) development and GPU-as-a-Service (GPUaaS) infrastructure. To efficiently operate large AI models, SKT will apply lightweight technology to A.X K1 and K2 and further train them with defense data to create AI models optimized for defense environments. The Defense Ministry will provide SKT with GPU resources secured through the Ministry of Science and ICT's 'National AI Project' in the second quarter of this year. SKT will utilize these resources to develop and demonstrate high-performance AI models and strengthen collaborative frameworks based on national research and development (R&D) infrastructure. Director Jeon stated, "This agreement will enable the rapid development and demonstration of defense-specific AI models based on the independent AI foundation model, marking a significant step forward for defense AI. We will continue to expand collaboration with the private sector." Choi Dong-won, director of AI Infrastructure Policy at the Ministry of Science and ICT, remarked, "This collaboration will be a crucial opportunity for our independent AI technology to be actively utilized in defense. We aim to create a virtuous cycle that revitalizes the domestic AI ecosystem." Kim added, "We will continue to expand AI utilization in sectors where data sovereignty and security are critical, such as finance, manufacturing, healthcare, and public services, to enhance K-AI competitiveness." Meanwhile, the Ministry of Science and ICT plans to conduct the second phase evaluation of the independent AI foundation model project around early August. This evaluation will focus not only on technical capabilities but also on the scalability and applicability of the technology in real-world industrial settings. The elite teams advancing to the second phase include SKT, LG AI Research Institute, Upstage, and Motif Technologies.* This article has been translated by AI. 2026-05-14 19:11:40